Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011

Dispatch

Klebsiella pneumoniae Bacteremia and Capsular Serotypes, Taiwan

Chun-Hsing Liao, Yu-Tsung Huang, Chih-Cheng Lai, Cheng-Yu Chang, Fang-Yeh Chu, Meng-Shiuan Hsu, Hsin-Sui Hsu, and Po-Ren Hsueh
Author affiliations: Author affiliations: Far Eastern Memorial Hospital, Taipei, Taiwan (C.-H. Liao, C.-C. Lai, C.-Y. Chang, F.-Y. Chu, M.-S. Hsu, H.-S. Hsu); National Taiwan University College of Medicine, Taipei (Y.-T. Huang, P.-R. Hsueh)

Main Article

Table A2

Distribution and clinical characteristics of 133 patients with community-onset Klebsiella pneumoniae bacteremia caused by different serotypes, Taiwan*

Characteristic K1 (n = 36) K2 (n = 22) Non-K1/K2 (n = 75) Univariate analysis (K1 vs. non–K1/K2)
Univariate analysis (K2 vs. non– K1/K2)
OR (95% CI) p value OR 95% CI p value
Age, y 60.6 ± 13.5 58.0 ± 15.6 63.7 ± 16.6 0.99 (0.96–1.01) 0.33 0.98 (0.95–1.01) 0.13
M:F 23:13 15:7 40:35 1.55 (0.68–3.51) 0.30 1.88 (0.69–5.12) 0.22
Severity of disease (McCabe classification)
Nonfatal 29 (80.6) 18 (81.8) 51 (68.0) 1.95 (0.75–5.078) 0.17 2.12 (0.65–6.94) 0.22
Ultimately fatal 5 (13.9) 3 (13.6) 17 (22.7) 0.55 (0.19–1.63) 0.28 0.54 (0.14–2.04) 0.36
Rapidly fatal 2 (5.5) 1 (4.6) 7 (9.3) 0.57 (0.11–2.90) 0.50 0.46 (0.05–3.98) 0.48
Pittsburgh bacteremia score 2.5 ± 2.7 3.2 ± 3.7 3.8 ± 4.6 0.91 (0.81–1.03) 0.13 0.97 (0.86–1.09) 0.60
Underlying illness, condition, or value
Diabetes mellitus 17 (47.2) 11 (50.0) 31 (41.3) 1.27 (0.57–2.83) 0.56 1.42 (0.55–3.68) 0.47
End-stage renal disease 1 (2.8) 0 5 (6.7) 0.40 (0.05–3.56) 0.41 NA NA
Heart disease 3 (8.3) 5 (22.7) 13 (17.3) 0.43 (0.12–1.63) 0.22 1.49 (0.44–4.49) 0.57
Stroke 3 (8.3) 3 (13.6) 9 (12.0) 0.67 (0.17–2.63) 0.56 1.16 (0.29–4.71) 0.84
Active malignancy 3 (8.3) 1 (4.6) 12 (16.0) 0.48 (0.13–1.81) 0.28 0.25 (0.03–2.04) 0.20
Liver cirrhosis 3 (8.3) 3 (13.6) 9 (12.0) 0.67 (0.17–2.63) 0.56 1.16 (0.29–4.71) 0.84
Surgery within 3 mo 2 (5.6) 0 10 (13.3) 0.38 (0.08–1.85) 0.23 NA NA
CT within 3 mo 1 (2.8) 0 3 (4.0) 0.69 (0.07–6.83) 0.75 NA NA
Creatinine level, mg/dL 1.7 ± 2.0 1.5 ± 1.2 1.9 ± 2.1 0.95 (0.77–1.18) 0.66 0.86 (0.62–1.19) 0.35
Albumin level, g/dL† 2.7 ± 0.6 2.6 ± 0.4 2.9 ± 0.6 0.63 (0.23–1.67) 0.35 0.33 (0.09–1.27) 0.11
Type of infection
Primary bacteremia 8 (22.2) 5 (22.7) 18 (24.0) 0.91 (0.35–2.33) 0.84 0.93 (0.30–2.88) 0.90
Respiratory tract 3 (8.3) 4 (18.2) 12 (16.0) 0.48 (0.13–1.81) 0.28 1.17 (0.34–4.06) 0.81
Urinary tract 2 (5.6) 3 (13.6) 17 (22.7) 0.20 (0.04–0.92) 0.039 0.54 (0.14–2.04) 0.36
Biliary tract 3 (8.3) 2 (9.1) 20 (26.7) 0.25 (0.07–0.91) 0.035 0.28 (0.06–1.28) 0.10
Liver abscess 18 (50.0) 5 (22.7) 6 (8.0) 11.5 (3.99–33.20) <0.001 3.38 (0.92–12.4) 0.07
Intraabdominal 1 (2.8) 2 (9.1) 1 (1.3) 2.1 (0.13–34.80) 0.60 7.40 (0.64–85.82) 0.11
Soft tissue 0 0 1 (1.3) NA NA NA NA
Meningitis 1 (2.8) 1 (4.6) 0 NA NA NA NA
TTP, h 13.6 ± 17.4 10.4 ± 3.0 15.6 ± 21.1 0.99 (0.97–1.02) 0.62 0.97 (0.90–1.04) 0.34
TTP<7 h 5 (13.9) 2 (9.1) 8 (10.7) 1.35 (0.41–4.47) 0.62 0.84 (0.34–2.09) 0.71
14-d mortality rate 3 (8.3) 3 (13.6) 13 (17.3) 0.43 (0.12–1.63) 0.22 0.75 (0.19–2.92) 0.68
In-hospital mortality rate 5 (13.9) 6 (27.3) 21 (28.0) 0.42 (0.14–1.21) 0.11 0.96 (0.33–2.80) 0.95
ESBL-producing strain 0 0 0 NA NA NA NA
Effective empirical agent 31 (86.1) 22 (100.0) 72 (96.0) 0.26 (0.06–1.15) 0.08 NA NA

*Values are mean ± SD or no. (%) unless otherwise indicated. OR, odds ratio; CI, confidence interval; NA, not applicable; CT, computed tomography; TTP, time to positive blood culture; ESBL, extended-spectrum β-lactamase.
†For K1 group, 24 patients; for K2 group, 25 patients; for non–K1/K2 group, 93 patients.

Main Article

TOP